Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM

Parkinson Disease Clinical Trial

— LATESTIM  

Official title:

A Prospective Randomized Controlled Trial of Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease With Motor Complications and Relative or Absolute Contraindications for Subthalamic Stimulation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02823158
• Other study ID #: 2016-000334
• Status: Terminated
• Phase: N/A
• Start date: September 2016
• Est. completion date: December 2018

Study information

• Verified date: October 2019
• Source: University Hospital Inselspital, Berne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Deep brain stimulation (DBS) is an established treatment for advanced complicated Parkinson's disease (PD). Several controlled randomized studies have given proof of an advantage for operated patients as compared to medically treated patients in terms of motor outcome, activities of daily living and health status. However these studies have addressed mostly stimulation of the subthalamic nucleus (STN). GPi stimulation has not been compared to best medical treatment (BMT) in a prospective randomized controlled trial in patients with complicated PD who are not good candidates for STN stimulation. The investigators aim assessing GPi-DBS in patients with PD who have contraindications for STN-DBS.

Description:

The indication and excellent therapeutic effects of STN stimulation have been sufficiently proven in advanced PD, and the contraindications for this treatment are rather well established. Also, the observation that patients fulfilling the "STN-profile" but who had been operated for pallidal DBS and lost part of the treatment's benefit over time, improved when stimulated later in the STN (instead of the GPi) shows that patients qualifying for STN-DBS do not have as good a result with GPi-DBS.

GPi stimulation may be used in patients who do not qualify for STN stimulation. Especially postural instability, age over 70 years, and mild to moderate cognitive deficits are commonly considered to be exclusion criteria for STN stimulation but not for GPi stimulation. Therefore, the investigators propose a prospective randomized controlled trial of GPi stimulation in patients with PD and motor complications who have relative or absolute contraindications for STN stimulation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Parkinson's disease according to the UKBB criteria, with the exception that familial forms of otherwise typical parkinsonian syndromes may also be included

• motor complications of dopaminergic medication (dyskinesia or motor fluctuations or both) that are at least moderately bothersome to the patient [on a scale of 5 possible levels: not at all / mildly / moderately / severely / extremely bothersome]

• Presence of at least one of the following absolute exclusion criteria for STN stimulation:

• Mattis dementia rating scale <130 points

• postural instability of >1 in the item of MDS-UPDRS III [item #12] "on" medication

• less than 30% improvement of axial score in the acute levodopa challenge test [axial score =sum of items 3.1, 3.9, 3.10, 3.12, 3.13 of the MDS UPDRS III]

• or presence of at least two of the following relative exclusion criteria for STN stimulation:

• age > 70 years

• Mattis dementia rating scale <134 points

• gait freezing "on" medication

• dysarthria of > 2 in the item of the MDS-UPDRS III [item #3.1]

• less than 50% improvement of axial score in the acute levodopa challenge test [axial score = sum of items 3.1, 3.9, 3.10, 3.12, 3.13 of the MDS UPDRS III]

• Starkstein apathy score of =14

• Complete baseline PDQ-39-SI and patient diary available

• written informed consent

Exclusion Criteria:

• Age > 85 years

• surgical or medical contraindications

• abnormalities on brain MRI that preclude the implantation of electrodes into the GPi

• contraindication for 3T MRI (baseline imaging)

• severe medical illness that is likely to hamper the benefit of DBS

• severe personality disorder that may interfere with optimization of DBS

• dementia according to DSM-V and MMSE < 20

• ongoing psychosis (except pseudohallucinations)

• ongoing major depression (BDI-II > 23) or depression of any severity with suicidal ideation

Related Conditions & MeSH terms

• Basal Ganglia Disease
• Basal Ganglia Diseases
• Central Nervous System Disease
• Central Nervous System Diseases
• Disease
• Ganglion Cysts
• Movement Disorders
• Nervous System Diseases
• Neurodegenerative Diseases
• Neurodegenerative Disorders
• Parkinson Disease

Intervention

Procedure:
• Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT)
Patients in the GPi group will be implanted with DBS-electrodes within 6 weeks after randomisation. The stimulation parameters and the medical treatment are adjusted for optimal control of motor and non-motor signs and symptoms according to published guidelines using a specified algorithm. The stimulation parameters are recorded at the beginning and at the end of each post-surgical assessment. Best medical treatment is applied in combination with GPi-DBS.
• Best medical treatment
Patients will receive optimized medical treatment according to published evidence based guidelines.

Locations

Country	Name	City	State
Switzerland	Inselspital University Hospital Bern	Bern

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Inselspital, Berne	Boston Scientific Corporation

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference of change of the score of the Parkinson's disease questionnaire 39 (PDQ-39-SI) from baseline to follow-up between the two treatment groups.		Baseline and 5 months +/- 1 month
Primary	Difference of change in number of hours per day spent in motor "on" without troublesome dyskinesia from baseline to follow-up between the two treatment groups.		Baseline and 5 months +/- 1 month
Secondary	Difference of change of the score of the MDS-UPDRS part III (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, part III) from baseline to follow up between the two trial groups.		Baseline and 5 months +/- 1 month
Secondary	Difference of change of the score of the MDS-UPDRS part IV (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, part IV) (MDS-UPDRS) from baseline to follow up between the two trial groups.		Baseline and 5 months +/- 1 month
Secondary	Difference of change in number of hours per day spent in motor "on" with troublesome dyskinesia from baseline to follow-up between the two treatment groups.		5 months +/- 1 months